Monday, January 12, 2015 9:58:10 AM
Recent AGEN News
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/24/2024 09:00:00 PM
- Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting • Business Wire • 05/23/2024 09:10:00 PM
- Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 05/23/2024 11:30:00 AM
- FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer • Business Wire • 05/16/2024 11:30:00 AM
- Agenus Reports First Quarter 2024 Results • Business Wire • 05/07/2024 11:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:39:11 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:38:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:31:13 AM
- Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement • Business Wire • 05/01/2024 11:30:00 AM
- Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting • Business Wire • 04/24/2024 02:00:00 PM
- Agenus to Provide First Quarter 2024 Financial Report and Corporate Update • Business Wire • 04/23/2024 11:30:00 AM
- Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer • Business Wire • 04/12/2024 11:30:00 AM
- Agenus Announces Reverse Stock Split of Common Stock • Business Wire • 04/05/2024 08:30:00 PM
- Agenus Reports Fourth Quarter and Full Year 2023 Results • Business Wire • 03/14/2024 11:30:00 AM
- Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 • Business Wire • 03/06/2024 12:30:00 PM
- Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/05/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/29/2024 09:50:48 PM
- Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report • Business Wire • 02/29/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/26/2024 09:24:59 PM
- Agenus to Participate in Leerink Partners Global Biopharma Conference • Business Wire • 02/26/2024 12:30:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/15/2024 01:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:00:11 PM
- Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design • PR Newswire (US) • 02/15/2024 12:02:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:33:12 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 12:00:12 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM